

Haematologica
HAEMATOL/2020/262006
Version 3

Eculizumab for complement mediated thrombotic microangiopathy in
sickle cell disease

Satheesh Chonat, Sara Graciaa, H. Stella Shin, Joanna G. Newton,
Maa-Ohui Quarmyne, Jeanne Boudreaux, Amy Tang, Patricia E. Zerra,
Margo R. Rollins, Cassandra D. Josephson, Clark Brown, Clinton H.
Joiner, Ross M. Fasano, and Sean R. Stowell

Disclosures: S.C. is a scientific advisor to Alexion and Agios pharmaceuticals. M.R.R. is a scientific advisor to Bluebird Bio. C.D.J. receives research funds from Terumo BCT, Octapharma, and Medtronic. The remaining authors declare no competing financial interests.

Contributions: S.C. collected and analyzed the data and wrote the manuscript. S.G., J.G.N., M.O.Q., J.B., A.T., P.E.Z., M.R., C.D.J. collected and analyzed the data and reviewed the manuscript. H.H.S., C.B., C.H.J., R.M.F. and S.R.S. analyzed the data and provided critical revisions to the manuscript.